ATE162719T1 - Ophthalmische zubereitung - Google Patents
Ophthalmische zubereitungInfo
- Publication number
- ATE162719T1 ATE162719T1 AT90912700T AT90912700T ATE162719T1 AT E162719 T1 ATE162719 T1 AT E162719T1 AT 90912700 T AT90912700 T AT 90912700T AT 90912700 T AT90912700 T AT 90912700T AT E162719 T1 ATE162719 T1 AT E162719T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- intraocular pressure
- glucocorticoid
- angiostatic steroid
- ophthalmic inflammation
- Prior art date
Links
- 239000003862 glucocorticoid Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000000964 angiostatic effect Effects 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000004410 intraocular pressure Effects 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003028 elevating effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/399,351 US4945089A (en) | 1987-12-29 | 1989-08-28 | Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids |
| US41922689A | 1989-10-10 | 1989-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE162719T1 true ATE162719T1 (de) | 1998-02-15 |
Family
ID=27016589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90912700T ATE162719T1 (de) | 1989-08-28 | 1990-07-25 | Ophthalmische zubereitung |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0489779B1 (de) |
| JP (1) | JPH05500054A (de) |
| AT (1) | ATE162719T1 (de) |
| AU (1) | AU637824B2 (de) |
| CA (1) | CA2064478C (de) |
| DE (1) | DE69032012T2 (de) |
| WO (1) | WO1991003245A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2680108B1 (fr) * | 1991-08-09 | 1993-11-19 | Theramex Sa Laboratoire | Nouvelles compositions pharmaceutiques a base de sterouides 6-hydroxymethyles et leur procede d'obtention. |
| EP1236470A3 (de) * | 1991-11-22 | 2004-09-01 | Alcon Laboratories, Inc. | Angiostatische Steroide |
| US5929111A (en) * | 1996-12-18 | 1999-07-27 | Alcon Laboratories, Inc. | A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| EP1252895A4 (de) * | 2000-01-31 | 2003-04-16 | Santen Pharmaceutical Co Ltd | Heilmittel für ophthalmologische zustände |
| PT1380302E (pt) * | 2001-03-28 | 2008-11-25 | Santen Pharmaceutical Co Ltd | Medicamentos para doenças da retina e coróide que contêm esteróides como ingrediente activo |
| EP3656385A1 (de) | 2008-05-28 | 2020-05-27 | ReveraGen BioPharma, Inc. | Nichthormonale steroide modulatoren von nf-kb zur behandlung von erkrankungen |
| US10799514B2 (en) | 2015-06-29 | 2020-10-13 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease |
| US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0088462A3 (de) * | 1982-03-01 | 1984-06-06 | The Procter & Gamble Company | Entzündungshemmende und antirheumatische Zusammensetzung mit Gehalt an einem Organophosphonat und einem Steroiden |
| US4688006A (en) * | 1985-10-02 | 1987-08-18 | Hughes Aircraft Company | Phase compensated hybrid coupler |
-
1990
- 1990-07-25 AT AT90912700T patent/ATE162719T1/de not_active IP Right Cessation
- 1990-07-25 AU AU62952/90A patent/AU637824B2/en not_active Ceased
- 1990-07-25 WO PCT/US1990/004071 patent/WO1991003245A1/en not_active Ceased
- 1990-07-25 EP EP90912700A patent/EP0489779B1/de not_active Expired - Lifetime
- 1990-07-25 JP JP2512212A patent/JPH05500054A/ja active Pending
- 1990-07-25 DE DE69032012T patent/DE69032012T2/de not_active Expired - Fee Related
- 1990-07-25 CA CA002064478A patent/CA2064478C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69032012T2 (de) | 1998-05-14 |
| EP0489779A1 (de) | 1992-06-17 |
| AU6295290A (en) | 1991-04-08 |
| CA2064478A1 (en) | 1991-03-01 |
| EP0489779B1 (de) | 1998-01-28 |
| DE69032012D1 (de) | 1998-03-05 |
| EP0489779A4 (en) | 1993-01-07 |
| AU637824B2 (en) | 1993-06-10 |
| CA2064478C (en) | 2002-07-02 |
| JPH05500054A (ja) | 1993-01-14 |
| WO1991003245A1 (en) | 1991-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1992019143A3 (en) | Method for the delivery of compositions to the ocular tissues | |
| HUT60630A (en) | Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature | |
| BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
| DK0595796T3 (da) | Fremgangsmåde til behandling af androgen-relaterede sygdomme | |
| ATE232540T1 (de) | Angiostatische steroide | |
| MX9302038A (es) | Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s. | |
| BR9707325A (pt) | Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma | |
| ATE153856T1 (de) | Zusammensetzung zur stimulierung des immunsystems | |
| KR950701350A (ko) | 부작용 감소와 동시에 인터페론을 이용한 질환의 치료방법 및 조성물(methods and compositions for the treatment of diseases with interferon while reducing side effects) | |
| BR9709097A (pt) | Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária | |
| ATE162719T1 (de) | Ophthalmische zubereitung | |
| WO2001030802A3 (en) | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies | |
| DE69822295D1 (de) | Verwendung von misoprostol und/oder misoprostolsäure zur behandlung von erektionsstörungen | |
| BR9405404A (pt) | Uso de compostos de terpeno para reduzida liberação de ácido aracdônico e de mediadores de inflamação | |
| KR910005858A (ko) | 지방산 요법 | |
| Kucera et al. | Effects of Symphytum ointment on muscular symptoms and functional locomotor disturbances | |
| MY105798A (en) | Treatment of leukocyte dysfunction with gm-csf. | |
| DK148890D0 (da) | Farmaceutisk praeparat | |
| DE69131517T2 (de) | Verwendung von Prostaglandin-E1 zur Behandlung männlicher erektiler Impotenz | |
| Selye | Prevention by catatoxic steroids of lithocholic acid-induced biliary concrements in the rat | |
| DK0432638T3 (da) | Kombinationspræparater omfattende chloramphenicol, gentamycin og nystatin som virksomme stoffer til topisk behandling af inflammatoriske hudsygdomme | |
| IT1097897B (it) | Derivati del piranocromone e composizione terapeutica comprendente gli stessi,per il trattamento di malattie allergiche | |
| NO20003510L (no) | Fett-bindende polymerer | |
| RU95105265A (ru) | Средство для лечения трофических язв и ожогов у больных лепрой | |
| Whitley et al. | Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |